CSI Market
Sign In | Register

Assembly Biosciences Inc (ASMB) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ASMB quarterly Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Assembly Biosciences Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-6.12
Depreciation & amortization0.13
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation4.68
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Stock Based Compensation Expense For Services-
Debt Conversion Converted Instrument Amount-
Investment Income Net Amortization Of Discount And Premium-
Accretion And Amortization Of Investments In Marketable Securities-
Noncash Rent Expense0.85
Increase Decrease In Contract With Customer Liability-36.10
Goodwill And Intangible Asset Impairment-
Increase Decrease In Accrued Research And Development Expenses0.11
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.97
Increase (Decrease) in Accounts Payable0.59
Increase (Decrease) in Other Accrued Liabilities0.89
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.05
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.10
Discontinued operations0.00
Net Cash flow from Operating Activities-41.09
Investing Activities
Capital Expenditures-0.07
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities116.43
Payments to Acquire Available-for-sale Securities, Debt-229.83
Real Estate Investments0.00
Redemption Of Marketable Securities-
Payments For Security Deposits Collected-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-113.47
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.56
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net85.26
Proceeds From Exercise Of Stock Options And Warrants-
Accrued Offering Cost Related To Issuance Of Common Stock-
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan0.73
Proceeds From Issuance Of Common Stocks Under Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Stock To Related Party-
Proceeds From Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Warrants In Private Placements To Related Party Net Of Issuance Costs42.79
Proceeds From The Issuance Of Common Stock And Warrants In A Registered Direct Offering Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations38.34
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities174.67
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-41.16
Total Cash Flow20.11
4 historic quarters locked

Sign in to unlock the full Assembly Biosciences Inc cash flow history.

Sign In Create Free Account

About Assembly Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-115992

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document